A wave of excitement over using marijuana medically to alleviate symptoms associated with a variety of disease had GW Pharmaceuticals rewarding investors with significant returns in 2014. However, recent stumbles in the company's pipeline have weighed on shares lately.
In the wake of news last month showing that its marijuana drug cannibidiol for the treatment of schizophrenia posted mixed results, investors knocked shares down by 14%. In the following slideshow, I offer up insight into GW Pharmaceuticals' hopes for marijuana medicine and what investors will be watching closely over the coming months.
Continue Reading Below
The article Why GW Pharmaceuticals Dropped 14% in September originally appeared on Fool.com.
Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.